Portland, OR, December 5, 2013 – MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to oncology drug developers, announced today that its tests will be highlighted in several presentations at the upcoming 55th Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10th in Atlanta, GA.
MolecularMD scientists will present two posters describing new molecular diagnostic methodologies for analysis of BCR-ABL1 in CML, the MRDx BCR-ABL Test and the ABL1 Phasing Test. The MRDx BCR-ABL Test is an exquisitely sensitive quantitative real-time PCR test that is appropriate for measuring minimal residual disease in CML patients, and monitoring patients in molecular remission, and the ABL1 Phasing Test uses a Next Generation Sequencing approach to enable determination of phasing of compound mutations in BCR-ABL1. Furthermore, in collaboration with ARIAD Pharmaceuticals, Inc. and its clinical investigators, clinical data from a study using the MolecularMD ABL1 Phasing Test will be presented in an oral session.
Portland, OR, November 6, 2013 – MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to oncology drug developers, announced today that it will be presenting a poster at each of four upcoming conferences: ASCO-EORTC-NCI Markers in Cancer, Circulating Nucleic Acids in Plasma and Serum (CNAPS VIII), Association for Molecular Pathology (AMP) Annual Meeting, and the 10th International Congress of the Society for Melanoma Research.
The presentations cover topics that highlight MolecularMD’s technical achievements in assay development addressing the challenges presented by the clinical need for comprehensive genotyping data using limited source material such as plasma circulating solid tumor DNA and FFPE biopsy tissue.
—PGDx’s Expertise in Cancer Whole Genome Mapping and Analysis Complements
MolecularMD’s Strengths in Oncology Molecular Testing—
BALTIMORE, MD, October 25, 2013 – Personal Genome Diagnostics Inc. (PGDx), today announced that it will collaborate with MolecularMD to market a suite of comprehensive personalized medicine services to oncology researchers and drug developers, adding PGDx’s expertise in Next-Generation Sequencing (NGS)-based cancer biomarker discovery to MolecularMD’s capabilities in the development, validation and global delivery of cancer companion diagnostics. The collaboration is designed to provide a unique specialized service to the pharmaceutical and biotechnology industry, seamlessly spanning the entire spectrum of genomic and clinical trial services used in new drug R&D and clinical development. Under the terms of the agreement, the two companies will co-market each other’s services to their pharmaceutical and biotechnology customers.
Portland, OR (October 17, 2013) – MolecularMD Corp., a molecular diagnostics company focused on providing the highest quality companion diagnostics and clinical trials support services to oncology drug developers, announced today that it will be presenting three posters at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 19-23 in Boston, MA. One presentation highlights MolecularMD’s custom Next Generation Sequencing panel for blood-based evaluation of solid tumor mutation status by sequencing regions of interest in circulating tumor DNA. The other two presentations demonstrate MolecularMD’s development and validation of robust immunohistochemistry assays for clinical trial applications.
Portland, OR (August 8, 2013) -- MolecularMD Corporation today announced that Dr. Glenn Miller has been appointed to the executive management team as Chief Technology Officer and Executive Vice President. Dr. Miller will play a principal role in expanding MolecularMD’s leadership in developing and delivering complete molecular diagnostic solutions that accelerate the development and commercialization of targeted cancer therapies.